RNase Inhibitor

Ribonuclease Inhibitor, Human Placenta
Catalog No. ON-039
Purity ＞95% by SDS-PAGE
Storage Condition -20℃
Source Recombinant E.coli

RNase Inhibitor

Ribonuclease Inhibitor, Human Placenta
Grade
GMP level
Amount/Package: 40kU / centrifuge tube
SKU: ON-039-KU040-P
Collections:  Biochemical Reagents Diagnostics Enzyme & Related Buffer for Diagnostics Enzyme & Related Buffer for mRNA Enzymes Enzymes & Buffers Enzymes for Diagnostics Enzymes for mRNA Synthesis mRNA Other Raw Materials RNases and inhibitors
Unit price:
$325.00

Price

$325.00
Taxes, discounts and Shipping calculated at checkout.
This variant is unavailable. Contact us if you have particular requirements.
Checkout

This Variant only supports customization. Please click the inquire button to submit a custom request.

Price/Order Inquiry

Shipping notes
Products on this site:
Currently ships to US and Canada.
For shipping worldwide, please contact us.
Order fulfillment: within 2 business days, if available.
US: 2-8 days (from CA by FedEx).
Canada: 5-10 days (excludes customs delays).

Related Products

Details

Product Information

Ribonuclease Inhibitor, Human Placenta is a recombinant human placental protein with specifically inhibits broad-spectrum RNase such as RNase A, RNase B and RNase C. It is not effective against RNase 1, RNase T1, S1 Nuclease, RNase H, Taq DNA polymerase, M-MLV Reverse Transcriptase and T7 RNA Polymerase. The 50kDa protein exerts its inhibitory effect by noncovalently binding to RNases at 1:1 ratio. The Ki value for binding of Ribonuclease Inhibitor, Human Placenta to RNase is approximately 10-14M.

Source: Recombinant E.coli
Concentration: 40U/μL
Unit Definition: One unit is defined as the amount of Recombinant Ribonuclease Inhibitor required inhibit the activity of 5ng of ribonuclease A by 50%. Activity is measured by the inhibition of hydrolysis of cytidine 2',3'-cyclic monophosphate by ribonuclease A.
Storage Buffer: 20mM HEPES-KOH (pH7.6), 50mM KCl, 8mM DTT, 50%(v/v) glycerol.

Key points of operation

  1. Ribonuclease Inhibitor is active over a broad pH range (pH5.5-9).
  2. Ribonuclease Inhibitor is used in the standard RT and in vitro transcription, and the final concentration is 1U/μL.
To prevent the release of active ribonuclease, temperatures greater than 50℃ and high concentrations of urea or other denaturing agents should be avoided.

Security Information

Storage Conditions: -20℃
Quality Assurance: Free of endonuclease, exonuclease, Nickase, RNase and latent RNase activities.
Physical Purity: ＞95% by SDS-PAGE.

Reference

1. Blackburn, P., Wilson, G. and Moore,S. J. Biol. Chem. 252, 5904-10(1977).

Specifications
  • Catalog No.
    ON-039
  • Source
    Recombinant E.coli
  • Purity
    ＞95% by SDS-PAGE
  • Storage Condition
    -20℃

Documentation
COA Contact Us

Product Information

Ribonuclease Inhibitor, Human Placenta is a recombinant human placental protein with specifically inhibits broad-spectrum RNase such as RNase A, RNase B and RNase C. It is not effective against RNase 1, RNase T1, S1 Nuclease, RNase H, Taq DNA polymerase, M-MLV Reverse Transcriptase and T7 RNA Polymerase. The 50kDa protein exerts its inhibitory effect by noncovalently binding to RNases at 1:1 ratio. The Ki value for binding of Ribonuclease Inhibitor, Human Placenta to RNase is approximately 10-14M.

Source: Recombinant E.coli
Concentration: 40U/μL
Unit Definition: One unit is defined as the amount of Recombinant Ribonuclease Inhibitor required inhibit the activity of 5ng of ribonuclease A by 50%. Activity is measured by the inhibition of hydrolysis of cytidine 2',3'-cyclic monophosphate by ribonuclease A.
Storage Buffer: 20mM HEPES-KOH (pH7.6), 50mM KCl, 8mM DTT, 50%(v/v) glycerol.

Key points of operation

  1. Ribonuclease Inhibitor is active over a broad pH range (pH5.5-9).
  2. Ribonuclease Inhibitor is used in the standard RT and in vitro transcription, and the final concentration is 1U/μL.
To prevent the release of active ribonuclease, temperatures greater than 50℃ and high concentrations of urea or other denaturing agents should be avoided.

Security Information

Storage Conditions: -20℃
Quality Assurance: Free of endonuclease, exonuclease, Nickase, RNase and latent RNase activities.
Physical Purity: ＞95% by SDS-PAGE.

Reference

1. Blackburn, P., Wilson, G. and Moore,S. J. Biol. Chem. 252, 5904-10(1977).

Why choose Hongene?

Trusted Partner in Nucleic Acid

Enjoy enterprise‑grade quality even with small batch orders.

Integrated Supply & Commercial Scale

With nearly 30 years of expertise, we control a secure supply chain for RNA raw materials and provide reliable GMP-grade oligo synthesis from research to commercial kilogram-scale production.

Proprietary Technology & IP

Our proprietary Chemoenzymatic Ligation Platform combines chemical andenzymatic methods, enabling high-putity, cost-effective, and large-scale production of RNA-based therapeutics.

Rigorous Quality

We implement multiple stringent QC steps, maintain ISO certifications, and ensure >99% batch-to-batch consistency, reducing scale-up and PPQ risks.

Manufacturing Scalability

Hongene operates a 1.67-million-square-foot oligonucleotide manufacturing facility featuring advanced equipment, including multiple OligoPilot™ and OligoProcess™ synthesizers ranging from 10 to 1,800 mmol. Its 48 flexible production lines enable seamless, one-stop scale-up of API production from gram-level quantities to metric tons, achieving purity of ≥98% while supporting compliance with NMPA, FDA, and EMA regulatory requirements.

Global Business Network

Our products and services reach over 40 countries and regions, supporting around 3,000 clients worldwide.

Global Business Distribution
40+
Countries & Regions
≈3000
Global Clients
54000L+
Annual NTP Production
58t+
Annual Amidites Production

Ask us anything!

Back to top